NICE Says Initial No To Epidyolex In England, But GW Pharma Remains Upbeat

 
• By Ian Schofield

Draft guidance from NICE has recommended against the use of GW Pharmaceuticals’ Epidyolex for refractory epilepsy, but the company believes it has the data needed to ensure a positive outcome to the appraisal.

Rejected
NICE has rejected Epidyolex but GW Pharma still hopes for a positive outcome

More from United Kingdom

More from Europe